Amoneta Diagnostics seeks, develops and qualifies innovative biomarkers for the development of diagnostics in the field of neurological diseases. The purpose of the Company is to translate new diagnosis methods for various neurodegenerative diseases into products, and to promote the use of these tests in clinical practice. Our know-how is based on the detection of blood biomarkers.

Currently our biomarker R&D program is dedicated to the clinical qualification of new biomarkers and diagnostic tools for the diagnosis and the follow-up of the Alzheimer’s disease.